HomeCompareGBCHF vs JNJ

GBCHF vs JNJ: Dividend Comparison 2026

GBCHF yields 4000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBCHF wins by $4.994481689239762e+42M in total portfolio value
10 years
GBCHF
GBCHF
● Live price
4000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.994481689239762e+42M
Annual income
$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00
Full GBCHF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GBCHF vs JNJ

📍 GBCHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBCHFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBCHF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBCHF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBCHF
Annual income on $10K today (after 15% tax)
$340,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GBCHF beats the other by $4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBCHF + JNJ for your $10,000?

GBCHF: 50%JNJ: 50%
100% JNJ50/50100% GBCHF
Portfolio after 10yr
$2.497240844619881e+42M
Annual income
$2,497,118,039,391,368,600,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GBCHF
No analyst data
Altman Z
-1713.2
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBCHF buys
0
JNJ buys
0
No recent congressional trades found for GBCHF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBCHFJNJ
Forward yield4000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.994481689239762e+42M$30.3K
Annual income after 10y$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.994465620575748e+42M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GBCHF vs JNJ ($10,000, DRIP)

YearGBCHF PortfolioGBCHF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$400,010,700$400,000,000.00$10,592$272.30+$400.00MGBCHF
2$14,954,099,039,486$14,953,671,028,037.38$11,289$357.73+$14954099.03MGBCHF
3$522,475,570,786,797,700$522,459,569,900,825,500.00$12,123$472.89+$522475570786.79MGBCHF
4$17,060,387,015,284,700,000,000$17,059,827,966,423,956,000,000.00$13,141$629.86+$17060387015284700.00MGBCHF
5$520,629,757,399,644,800,000,000,000$520,611,502,785,538,400,000,000,000.00$14,408$846.81+$520629757399644831744.00MGBCHF
6$14,848,629,939,995,690,000,000,000,000,000$14,848,072,866,155,271,000,000,000,000,000.00$16,021$1,151.60+$1.4848629939995692e+25MGBCHF
7$395,786,651,827,842,740,000,000,000,000,000,000$395,770,763,793,806,900,000,000,000,000,000,000.00$18,122$1,588.22+$3.9578665182784276e+29MGBCHF
8$9,859,464,902,403,675,000,000,000,000,000,000,000,000$9,859,041,410,686,219,000,000,000,000,000,000,000,000.00$20,930$2,228.20+$9.859464902403675e+33MGBCHF
9$229,542,483,200,980,940,000,000,000,000,000,000,000,000,000$229,531,933,573,535,350,000,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$2.2954248320098093e+38MGBCHF
10$4,994,481,689,239,762,000,000,000,000,000,000,000,000,000,000,000$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.994481689239762e+42MGBCHF

GBCHF vs JNJ: Complete Analysis 2026

GBCHFStock

Metaverse Capital Corp. engages in controlling computing power for mining cryptocurrencies, operating masternodes/servicenodes, and providing witness services. The company's professional consultancy services include crowdsale administration services, as well as advisory services related to the development of blockchain networks. It also provides digital asset pooling operations that combines digital assets from various clients to operate masternodes on two-tier proof-of-stake blockchain networks. The company was formerly known as Global Blockchain Mining Corp. and changed its name to Metaverse Capital Corp. in May 2019. Metaverse Capital Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Full GBCHF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GBCHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBCHF vs SCHDGBCHF vs JEPIGBCHF vs OGBCHF vs KOGBCHF vs MAINGBCHF vs ABBVGBCHF vs MRKGBCHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.